MedPath

se of Convalescent Plasma in the treatment of COVID-19

Not Applicable
Recruiting
Conditions
COVID-19.
COVID-19, virus identified
U07.1
Registration Number
IRCT20200414047072N1
Lead Sponsor
Hilton Pharma Pvt. Ltd.
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Recruiting
Sex
All
Target Recruitment
357
Inclusion Criteria

Inclusion Criteria for Donors; Volunteer enrollment (Informed consent will be obtained; Annexures-2A & 2B).
All the regulations related to ICH-GCP and Blood Transfusion Authority (BTA) Pakistan will be followed.
Should fulfill all the criteria of a healthy blood donor (with the exception of history of COVID-19 during last 4-8 weeks.
History of COVID-19 during last 4-8 weeks.
RT-PCR negative for SARS-CoV-2 RNA (carried out on nasopharyngeal or oropharyngeal specimen).
Age cutoff: 18-55 years.
Body weight cut off: >50 kg for men and > 45 kg for women.
At least a week been passed since last use of glucocorticoids.
A minimum of 2-week duration been passed since complete recovery.
Inclusion Criteria for Recipients: Volunteer enrollment (Informed consent will be obtained; Annexures-3A & 3B).
Confirmed COVID-19 cases confirmed by RT-PCR laboratory tests.
Severe or Critical COVID-19 related features (8):
(a)Severe COVID-19, defined by the presence of any of the following features: i.Shortness of breath. ii.Respiratory rate = 30/min, iii. Arterial blood oxygen saturation = 93%, iv.Lung infiltrates > 50% within 24 to 48 hours
(b)Critical COVID-19, defined by the presence of any of the following features: i.Respiratory failure, ii.Shock iii.Multiple organ dysfunction

Exclusion Criteria

Allergy history for plasma, sodium citrate and methylene blue
For patients with history of autoimmune system diseases or selective IgA deficiency, the application of convalescent plasma should be evaluated cautiously by clinicians.
Patients having evidence of uncontrolled cytokine release syndrome leading to end-stage multi organ failure.

Study & Design

Study Type
interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Fever. Timepoint: registration day and week 4. Method of measurement: thermometer will be used for physical examination to check fever.;Resolution of infection. Timepoint: 28 days. Method of measurement: Two non-reactive Nucleic Acid Tests (NAT) for SARS-CoV-2 performed at an interval of at least 24 hours on nasopharyngeal swabs.;Lung infiltrates. Timepoint: registration day and week 4. Method of measurement: X-ray will be used.;Arterial blood oxygen saturation. Timepoint: registration day and week 4. Method of measurement: Lab test (blood from artery will used).;Respiratory rate. Timepoint: registration day and week 4. Method of measurement: physical examination was conducted to measure the breath rate by counting chest or abdomen rises number over a minute.
Secondary Outcome Measures
NameTimeMethod
© Copyright 2025. All Rights Reserved by MedPath